FluoGuide (FLOU) Q4 2025 earnings summary

Executive summary

• Achieved regulatory alignment with FDA for lead indications and U.S. Phase 2 trial of FG001, de-risking the path to approval and commercialization.

• Positive Phase II and interim results for FG001 in high-grade glioma, meningioma, low-grade glioma, and head and neck cancer; expanded partnerships with Olympus, ZEISS, and other MedTech firms.

• Strengthened management and leadership team, completed capital raises to fund clinical and regulatory milestones.

Financial highlights

• Full-year net loss of DKK 39.5 million, with Q4 2025 net loss of DKK 13.1 million.

• Assets totaled DKK 88 million, with DKK 79 million in cash and securities at year-end.

• Equity stood at DKK 55 million, with a loan of DKK 28 million and working capital payables of DKK 5 million.

• Cash flow from financing activities in 2025 was DKK 97.0 million, mainly from capital increases and credit facilities.

• Market cap at year-end DKK 389 million, up from DKK 370 million a year earlier.

Outlook and guidance

• First U.S. patient enrollment in registration trial expected in the first half of 2026.

• Interim results from low-grade glioma and head and neck studies anticipated in the second half of the year.

• Plans to present a comprehensive brain tumor strategy and PDT optimization plan later in the year.

• Expects to secure an additional commercial partnership during the year.

• Long-term objective is first U.S. drug approval for FG001 and broadening its use as a photosensitizer.